Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | ELANE | P08246 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | C1R | P00736 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1589852 | 1.00 | NPC1 (0.72) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL12723717 | 0.92 | NPC1 (0.70) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL1590366 | 0.91 | NPC1 (0.71) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL1590369 | 0.91 | NPC1 (0.71) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL1589946 | 0.91 | NPC1 (0.71) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL1589944 | 0.91 | NPC1 (0.71) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL134146 | 0.90 | NPC1 (0.67) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL8640703 | 0.88 | NPC1 (0.54) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL8640711 | 0.88 | NPC1 (0.54) | NPC1RAB9AELANEALDH1A1HPGD | |
| SCHEMBL1591009 | 0.88 | NPC1 (0.59) | NPC1RAB9AELANEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5097825-A | — | — | None | — | — | JP | disclosed |
| JP-5097825-A | — | — | None | — | — | JP | disclosed |
| EP-2947073-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2019-04-03 | — | — | EP | disclosed |
| US-9951087-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2018-04-24 | — | — | US | disclosed |
| EP-2947073-A2 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics Pty Ltd (AU) | 2015-11-25 | — | — | EP | disclosed |
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-09-24 | — | — | US | disclosed |
| EP-2491030-B1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-07-15 | — | — | EP | disclosed |
| US-9062076-B2 | Fused ring analogues of anti-fibrotic agents | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2015-06-23 | — | — | US | disclosed |
| US-20130338151-A9 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2013-12-19 | — | — | US | disclosed |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-10-25 | — | — | US | disclosed |
| EP-2491030-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | Fibrotech Therapeutics PTY LTD (AU) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047432-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2011-04-28 | — | — | WO | disclosed |
| EP-0855387-A1 | 2-ACYLAMINOBENZAMIDE DERIVATIVES AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY THE SUPERMULTIPLICATION OF VASCULAR INTIMAL CELLS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| EP-0452504-B1 | N-(3',4'-DIMETHOXYCINNAMOYL)ANTHRANILIC ACID | KOHJIN CO (JP) | 1994-10-12 | — | — | EP | disclosed |
| US-5223639-A | PROCESS FOR PRODUCING N-(3', 4'-DIMETHOXYCINNAMOYL)-ANTHRANILIC ACID | KOHJIN CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| JP-H0597825-A | PRODUCTION OF 2-(3,4-DIMETHOXYSTYRYL)-3,1-BENZOXAZIN-4-ONE | KISSEI PHARMACEUT CO LTD | 1993-04-20 | — | — | JP | disclosed |
| JP-H0597825-A | PRODUCTION OF 2-(3,4-DIMETHOXYSTYRYL)-3,1-BENZOXAZIN-4-ONE | KISSEI PHARMACEUT CO LTD | 1993-04-20 | — | — | JP | disclosed |
| EP-0452504-A1 | N-(3',4'-DIMETHOXYCINNAMOYL)ANTHRANILIC ACID | KOHJIN CO. Ltd. (JP) | 1991-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266893-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | NPC1 1936/4885RAB9A 2239/4885ELANE 35/4885 |
| US-20120270863-A1 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | NPC1 1936/4885RAB9A 2239/4885ELANE 35/4885 |
| US-20130338151-A9 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS | MMP1, FIBP, COL2A1 | NPC1 1936/4885RAB9A 2239/4885ELANE 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.